Pelthos Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Pelthos has rapidly grown ZELSUVMI prescriptions and revenue, with strong payer coverage and a robust cash position. Upcoming launches of Xepi and Xeglyze will leverage existing sales channels, while patent protection and proprietary manufacturing support long-term growth.
-
Recent commercial launch of ZELSUVMI for pediatric molluscum contagiosum has exceeded expectations, driving strong revenue growth and rapid prescriber adoption. Portfolio expansion with Xepi and Xeglyze leverages existing infrastructure, while robust patent protection and financial position support future growth.
Fiscal Year 2025
-
Q4 2025 saw strong revenue growth and reduced losses, driven by ZELSUVMI's rapid uptake and expanded coverage. Two FDA-approved product acquisitions and new financing position the company for continued growth and expected profitability by year-end 2026.
-
A major payer win expands access for Zelsuvmi, driving rapid prescription growth and supporting a salesforce expansion. Zelsuvmi, the only FDA-approved at-home molluscum treatment, and newly acquired Xepi for impetigo, both target large pediatric markets with strong market access and IP protection.
-
Q3 2025 saw a strong ZELSUVMI launch, generating $7.1M in revenue and rapid prescription growth, supported by expanded sales force and new financing. The company expects to reach cash flow break-even by end of 2026 and projects continued revenue growth, with Xepi launch planned for late 2026.